I think it’s utility and its value in the ICU is further supported by a statistic that Nabeel gave, which is that 80% of our console sales last quarter had the Tablo PRO+ software attached to it, which is a feature, the 24-hour feature that you would only use in the ICU. And so I think that speaks to the value — clinical value that Tablo delivers in the ICU. And none of that is changed as a result of the warring letter, the competitive activity around it, which is the good news.
Joshua Jennings: Excellent. And then just one follow-up on the home opportunity. I think you’ve called out just the stat about 40% of the U.S. dialysis population having Medicare Advantage and then payers ultimately may drive more patients to the home to secure an economic benefit. Can you just — have there been any actions by payers to date or do you expect any in 2024? Or how can that evolve? Maybe just remind us of how economic beneficial home is for these payers. Thanks a lot.
Leslie Trigg: Yeah. Of course. I’m happy to. Well, and maybe I’ll take a half step back and say, I think all of the structural tailwinds and kind of the more foundational growth drivers for home are all still firmly intact. As a reminder, the ETC model from CMS is in place and providing increasing benefits or increasing incentives, I should say, between now and 2027. So that model, we believe, will continue to incent providers of all types to send more patients home quickly. We do still see patient preferences being influenced in a positive way towards home as a result of COVID. I think patients are more confident sort of forward leaning to our homes than ever. And that’s also aided by, I think, kind of the normalization of the hospital to home environment and movement.
And then the third big structural tailwind is one that you cited. Yes, we do continue to see data that roughly 40% of the dialysis population is already signed up for Medicare Advantage. These payers prior to Medicare Advantage eligibility for dialysis patients used to be able to transition their commercial patients over to Medicare at month 30, and now that’s no longer the case. So they will be supporting their dialysis members effectively in perpetuity. And so we do expect to see increasing involvement amongst the Medicare Advantage providers to urge their partners to move more patients into the home. I’ll say, as I said a couple of minutes ago, I think transformation at this level in any market rarely happens overnight. And so I would not necessarily expect to have results to report back to you on that next quarter per se.
But in almost every conversation we are having with payers, it involves a discussion around how do we move more patients home. We believe that the cost of care is lower and that the quality of care is higher in the home. So the conviction and the belief and the motivation is certainly already present.
Joshua Jennings: Great. Thanks so much.
Operator: Thank you. This does conclude the question-and-answer session of today’s program. I’d like to hand the program back to Leslie Trigg for any further remarks.
Leslie Trigg: Thank you, and thanks to all of you for joining today. We look forward to our next update on our first quarter call, and hope you all have a great evening.
Operator: Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.
